Avacta launches new product in vets

HEALTHCARE company Avacta Group has launched its in-clinic blood analysis system, Sensipod, to veterinary practices in the UK along with the first point of care test to screen dogs for environmental allergies.

The AIM-listed Wetherby-based company, which provides innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, said the system is being launched in the UK with its first test, a canine environmental allergy pre-screen that assists the veterinarian in identifying allergies in dogs.

Avacta is currently developing a large panel of additional tests for Sensipod covering common diseases in dogs, cats and horses, as well as other novel tests, which will provide a unique bench-top diagnostic capability for the veterinarian.
 
Alastair Smith, chief executive of Avacta Group said: “I am absolutely delighted that Sensipod has now launched and is in the hands of veterinarians. A huge amount of hard work and innovation has delivered a product that we believe has massive potential in the veterinary market. Growth of the test menu is key to realising that potential. We are making good progress in that area and anticipate reporting the launch of a number of new tests during this financial year. Our initial focus for commercialisation of Sensipod is the UK and we have plans to address other geographical markets as the test menu grows.

“New reference laboratory tests and diagnostic kits will be added to our wider diagnostics portfolio as a by-product of the Sensipod test menu development programme allowing us to add to the core Animal Health offering beyond allergy which is an additional growth driver for the business.”